- Home
- MHUA vs PRTG Comparison
MHUA vs PRTG Comparison
Compare MHUA & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- PRTG
- Stock Information
- Founded
- MHUA 1990
- PRTG 1973
- Country
- MHUA China
- PRTG British Virgin Islands
- Employees
- MHUA N/A
- PRTG N/A
- Industry
- MHUA Medical Specialities
- PRTG Oil & Gas Production
- Sector
- MHUA Health Care
- PRTG Energy
- Exchange
- MHUA Nasdaq
- PRTG Nasdaq
- Market Cap
- MHUA 19.6M
- PRTG 17.7M
- IPO Year
- MHUA 2022
- PRTG N/A
- Fundamental
- Price
- MHUA $0.41
- PRTG $5.56
- Analyst Decision
- MHUA
- PRTG
- Analyst Count
- MHUA 0
- PRTG 0
- Target Price
- MHUA N/A
- PRTG N/A
- AVG Volume (30 Days)
- MHUA 245.9K
- PRTG 24.0K
- Earning Date
- MHUA 04-25-2025
- PRTG 08-14-2025
- Dividend Yield
- MHUA N/A
- PRTG N/A
- EPS Growth
- MHUA N/A
- PRTG N/A
- EPS
- MHUA 0.40
- PRTG N/A
- Revenue
- MHUA $96,909,642.00
- PRTG N/A
- Revenue This Year
- MHUA N/A
- PRTG N/A
- Revenue Next Year
- MHUA N/A
- PRTG N/A
- P/E Ratio
- MHUA $1.03
- PRTG N/A
- Revenue Growth
- MHUA N/A
- PRTG N/A
- 52 Week Low
- MHUA $0.25
- PRTG $2.10
- 52 Week High
- MHUA $1.47
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- MHUA 49.99
- PRTG 31.60
- Support Level
- MHUA $0.30
- PRTG $7.51
- Resistance Level
- MHUA $0.41
- PRTG $8.17
- Average True Range (ATR)
- MHUA 0.08
- PRTG 0.71
- MACD
- MHUA -0.01
- PRTG -0.26
- Stochastic Oscillator
- MHUA 32.09
- PRTG 1.60
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.